El uso de compuestos de cannabis para la farmacoterapia de la enfermedad de Gilles de la Tourette
Resumen
Objetivo: analizar la relación medicinal del Cannabis con el Síndrome de Tourette. Métodos: la presente revisión integrativa de la literatura utilizó las bases de datos PubMed, LILACS, MedLine, SciELO y Science Direct para filtrar los artículos publicados en los últimos cinco años, disponibles en su totalidad en los idiomas inglés, portugués o español, cuyo enfoque fuera el uso de estos compuestos en el tratamiento de dicho trastorno. Resultados: la eficacia del tratamiento varía según la dosificación y la vía de administración, siendo comunes los efectos adversos leves, como sedación, xerostomía y mareos, lo que evidencia el desafío en la estandarización y homogeneidad de los tratamientos en las nuevas evidencias. Conclusión: a pesar de los resultados prometedores, estos aún son inconclusos e insuficientes para fundamentar una recomendación clínica. Se requieren más estudios futuros con metodologías rigurosas y muestras más amplias para confirmar la eficacia del Cannabis en el tratamiento de este trastorno.
Descargas
Citas
Maiola R. Georges Gilles de la Tourette. Medicina (B Aires). 2022;82(3):459–60.
American Psychiatric Association. DSM-5: Manual diagnóstico e estatístico de transtornos mentais. Porto Alegre: Artmed; 2014.
Nieto-Pico AM, Rueda-Vargas A, Mora-Bautista VM. Trastornos por tics en niños: un caso con retraso diagnóstico. Ces Med. 2019;33(2):126–33.
Fernández S, Larraguibel Q. Síndrome de Tourette: Tratamiento farmacológico en pacientes pediátricos, una puesta al día. Rev Chil Psiquiatr Neurol Infanc Adolesc. 2020;31(2):91–104.
Anis S, Davidov A, Ben‐Ari Y, Pellegrino G, Snir Y, Goldstein M, et al. Medical Cannabis for Gilles de la Tourette syndrome: An open‐label prospective study. Behav Neurol. 2022;2022:5141773.
Dyke K, Naros G, Hidding U, Rogalewski A, Bäumer T, Dresel C, et al. Effects of single-session cathodal transcranial direct current stimulation on tic symptoms in Tourette's syndrome. Exp Brain Res. 2019;237(11):2853–63.
Singer HS, Augustine F. Controversies surrounding the pathophysiology of tics. J Child Neurol. 2019;34(13):851–62.
Roessner V, Hoekstra PJ, Rizzo R, Stern JS, Mathews CA, Porta M, et al. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2022;31(3):403–20.
Müller-Vahl KR, Roessner V, Rizzo R, Jakubovski E, Stern JS, Hoekstra PJ, et al. European clinical guidelines for Tourette syndrome and other tic disorders: summary statement. Eur Child Adolesc Psychiatry. 2022;31(3):377–82.
Groh CJ. Medical Cannabis and psychiatric disorders: Implications for psychiatric nurses. J Am Psychiatr Nurses Assoc. 2022;28(1):91–103.
Szejko N, Jakubovski E, Müller-Vahl KR. Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. Neurol Neurochir Pol. 2022;56(1):28–38.
Brasil. Conselho Federal de Medicina. Resolução CFM nº 2.324, de 11 de outubro de 2022. Diário Oficial da União, Brasília, DF; 2022 Oct 14.
Efron D, Taylor K. Medicinal Cannabis for paediatric developmental, behavioural and mental health disorders. Int J Environ Res Public Health. 2023;20(8):5430.
Hoch E, Niemann D, von Keller R, Schneider M, Friemel CM, Preuss UW, et al. How effective and safe is medical Cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2019;269:87–105.
Klumpers LE, Thacker DL. A brief background on Cannabis: From plant to medical indications. J AOAC Int. 2019;102(2):412–20.
Bloch MH, Panza KE, Landeros-Weisenberger A, Brennan BD, Leckman JF, Pittenger C. A phase-2 pilot study of a therapeutic combination of Δ9-tetrahydracannabinol and palmitoylethanolamide for adults with Tourette’s syndrome. J Neuropsychiatry Clin Neurosci. 2021;33(4):328–36.
Müller-Vahl KR. Cannabinoids in the treatment of selected mental illnesses: Practical approach and overview of the literature. Pharmacopsychiatry. 2024;57(1):14–23.
Schwittay MA, Steinbrecher A, Lobsien E. Tic reduction in adult onset Gilles De La Tourette syndrome using as required Nabiximols spray. Tremor Other Hyperkinet Mov. 2021;11:30.
Aran A, Cayam-Rand D. Medical Cannabis in children. Rambam Maimonides Med J. 2020;11(1):e0002.
Müller-Vahl KR, Pisarenko A, Jakubovski E, Fremer C, Schürmann M, Kolbe H, et al. Endocannabinoid modulation using monoacylglycerol lipase inhibition in Tourette syndrome: a phase 1 randomized, placebo-controlled study. Pharmacopsychiatry. 2022;55(3):148–56.
Müller-Vahl KR, Jakubovski E, Schürmann M, Kolbe H, Davies P, Pisarenko A, et al. CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter, randomized, double-blind, placebo-controlled, phase IIIb superiority study. Psychiatry Res. 2023;323:115135.
Serag I, ElSayed M, Abdelrahman S, Elbarbary M. Efficacy of Cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2024;80(10):1483–93.
Müller-Vahl KR, Jakubovski E, Pisarenko A, Fremer C, Kolbe H, Schürmann M, et al. Monoacylglycerol lipase inhibition in Tourette syndrome: a 12-week, randomized, controlled study. Mov Disord. 2021;36(10):2413–8.
Jakubovski E, Martino D, Müller-Vahl KR. The CANNA-TICS study protocol: a randomized multi-center double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders. Front Psychiatry. 2020;11:575826.
Mosley PE, Herbert A, Malpas G, Dwyer J, Martin JH. Tetrahydrocannabinol and cannabidiol in Tourette syndrome. NEJM Evid. 2023;2(9):EVIDoa2300012.
Lasch F, Trottmann M, Goetz S, Jakubovski E, Müller-Vahl KR. Potential impact of COVID‐19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA‐TICS study. Pharm Stat. 2021;20(3):675–91.
Szejko N, Roessner V, Rizzo R, Jakubovski E, Hoekstra PJ, Müller-Vahl KR. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part I: assessment. Eur Child Adolesc Psychiatry. 2022;31(3):383–402.
Derechos de autor 2026 Arquivos do Mudi
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
DECLARAÇÃO DE ORIGINALIDADE E DIREITOS AUTORAIS
Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade.
Os direitos autorais pertencem exclusivamente aos autores. Os direitos de licenciamento utilizados pelo periódico é a licença Creative Commons Attribution 4.0 (CC BY ): são permitidos o acompartilhamento (cópia e distribuição do material em qualqer meio ou formato) e adaptação (remix, transformação e criação de material a partir do conteúdo assim licenciado para quaisquer fins, inclusive comerciais.
Recomenda-se a leitura desse link para maiores informações sobre o tema: fornecimento de créditos e referências de forma correta, entre outros detalhes cruciais para uso adequado do material licenciado.
